323 related articles for article (PubMed ID: 29995258)
1. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
Patel N; Wisniowska B; Polak S
AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
4. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.
Patel N; Hatley O; Berg A; Romero K; Wisniowska B; Hanna D; Hermann D; Polak S
AAPS J; 2018 Mar; 20(3):47. PubMed ID: 29541956
[TBL] [Abstract][Full Text] [Related]
5. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
8. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
9. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
Hondeghem LM
J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
[TBL] [Abstract][Full Text] [Related]
10. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1206-1213. PubMed ID: 27333947
[TBL] [Abstract][Full Text] [Related]
13. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans.
Valentin JP; Hoffmann P; Ortemann-Renon C; Koerner J; Pierson J; Gintant G; Willard J; Garnett C; Skinner M; Vargas HM; Wisialowski T; Pugsley MK
Toxicol Sci; 2022 Apr; 187(1):3-24. PubMed ID: 35148401
[TBL] [Abstract][Full Text] [Related]
14. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
15. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
16. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
17. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic issues in thorough QT trials.
Judson RS; Salisbury BA; Reed CR; Ackerman MJ
Mol Diagn Ther; 2006; 10(3):153-62. PubMed ID: 16771601
[TBL] [Abstract][Full Text] [Related]
19. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
20. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
